<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05610176</url>
  </required_header>
  <id_info>
    <org_study_id>BA115</org_study_id>
    <nct_id>NCT05610176</nct_id>
  </id_info>
  <brief_title>BIO|CONCEPT.Amvia Study</brief_title>
  <official_title>BIO|CONCEPT.Amvia, First in Human Study for the Amvia/Solvia Pacemaker Family</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik Australia Pty Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biotronik SE &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Biotronik SE &amp; Co. KG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this exploratory study is to test the preliminary safety and product performance&#xD;
      of the new Amvia/Solvia pacemaker family in subjects that require a pacemaker or cardiac&#xD;
      resynchronization therapy pacemaker (CRT-P) implantation. The study will be conducted at&#xD;
      sites in Australia and New Zealand. It is planned to include 50 subjects in the study.&#xD;
      Participants will visit sites at enrollment in the study, at implantation, pre-hospital&#xD;
      discharge, 1- 3- and 12-month follow-up visits. At the visits the device will be interrogated&#xD;
      and standard device measurements including those related to special features will be&#xD;
      performed to assess the functionality of the device. Programming of the pacemakers will be&#xD;
      done according to the participantÂ´s therapeutical needs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 23, 2022</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serious adverse device effect (SADE)-free rate after 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Descriptive statistics of the investigational device related SADE-free rate after first implantation attempt will be calculated using a Kaplan-Meier estimate</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Bradycardia</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Amvia Sky pacemaker or CRT-P implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients implanted with an Amvia Sky pacemaker or CRT-P device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Amvia Sky pacemaker or CRT-P device</intervention_name>
    <description>Subjects with an indication for a pacemaker or CRT-P device will be implanted with an Amvia Sky device of the Amvia/Solvia pacemaker family according to standard pacemaker implantation procedures. Device programming will be done according to the medical needs of the subjects.</description>
    <arm_group_label>Amvia Sky pacemaker or CRT-P implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Standard indication for pacemaker or cardiac resynchronization therapy pacemaker&#xD;
             (CRT-P) implantation, including de novo, upgrade or replacement implantations&#xD;
&#xD;
          -  Ability to understand the nature of the study&#xD;
&#xD;
          -  Willingness to provide written informed consent&#xD;
&#xD;
          -  Ability and willingness to perform all follow-up visits at the study site&#xD;
&#xD;
          -  Ability and willingness to use the CardioMessenger and acceptance of the BIOTRONIK&#xD;
             Home Monitoring concept&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Planned for conduction system pacing&#xD;
&#xD;
          -  Planned for activation of atrial anti-tachycardia pacing (aATP) without known history&#xD;
             of atrial arrhythmia, or with permanent atrial fibrillation (AF)&#xD;
&#xD;
          -  Planned cardiac surgical procedures or interventional measures other than the study&#xD;
             procedure within the next 12 months&#xD;
&#xD;
          -  Pregnant or breast feeding&#xD;
&#xD;
          -  Age less than 18 years&#xD;
&#xD;
          -  Participation in another interventional clinical investigation according to the&#xD;
             definition given in the study protocol&#xD;
&#xD;
          -  Life-expectancy less than 12 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Justin Mariani, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Alfred</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Simone Froemer</last_name>
    <phone>+49 30 68905</phone>
    <phone_ext>0</phone_ext>
    <email>Amvia-concept@biotronik.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mathias Freudigmann</last_name>
    <phone>+49 30 68905</phone>
    <phone_ext>0</phone_ext>
    <email>mathias.freudigmann@biotronik.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Justin Mariani, A/Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>December 2022</verification_date>
  <study_first_submitted>November 2, 2022</study_first_submitted>
  <study_first_submitted_qc>November 2, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2022</study_first_posted>
  <last_update_submitted>December 16, 2022</last_update_submitted>
  <last_update_submitted_qc>December 16, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiac pacemaker</keyword>
  <keyword>CRT-P</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bradycardia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

